Ubrogepant treatmeNt in mIgraine Patients Utilizing mOnoclonal aNtibodies

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Clinical Phase

PHASE4

Total Enrollment

164 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-09-06

Study Completion Date

2024-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a prospective open-label randomized study assessing similar endpoints included in the pivotal trial for ubrogepant, which are pain freedom and freedom from the most bothersome symptom at two hours. Patients between 18-75 years old with a one-year history of migraine who experience ≥3 migraine days/month will be screened. This study will include migraine patients treated with or without injectable CGRPmAbs. As was the case in the clinical trials, this will be a single-attack study. Patients will be randomized to treat a single migraine attack with ubrogepant 50mg or 100mg. Patients will record dosing time, most bothersome symptom (nausea, photophobia, or phonophobia - chosen by patient), pain freedom, pain relief, the use of a 2nd dose if required, and adverse reactions. Patients will follow up within 30 days post treatment. Patients will be assessed for adverse events, and the safety data will be compared with the original clinical trial.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine

NCT02828020

Migraine, With or Without Aura

COMPLETED PHASE3

Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine

NCT02867709

Migraine, With or Without Aura

COMPLETED PHASE3

Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants

NCT04492020

Migraine

COMPLETED PHASE3

An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine

NCT02873221

Migraine, With or Without Aura

COMPLETED PHASE3

Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine

NCT05264129

Episodic Migraine

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to examine the safety and efficacy of ubrogepant (UBRELVY) in patients currently treated with one of the injectable monoclonal antibodies targeting CGRP or the CGRP receptor (Aimovig, Ajovy, or Emgality). There are currently very limited data available about the use of CGRP receptor antagonists in this population, resulting in difficulty obtaining prior authorization to use ubrogepant in patients currently treated with CGRPmAbs. Questions remain as to whether these patients, whose CGRP or CGRP receptors are suppressed, will experience the same safety and efficacy results as patients without such suppression by CGRPmAbs.

This is a prospective open-label randomized study assessing similar endpoints included in the pivotal trial for ubrogepant, which are pain freedom and freedom from the most bothersome symptom at two hours. Patients between 18-75 years old with a one-year history of migraine who experience ≥3 migraine days/month will be screened. This study will include migraine patients treated with or without injectable CGRPmAbs. As was the case in the clinical trials, this will be a single-attack study. Patients will be randomized to treat a single migraine attack with ubrogepant 50mg or 100mg. Patients will record dosing time, most bothersome symptom (nausea, photophobia, or phonophobia - chosen by patient), pain freedom, pain relief, the use of a 2nd dose if required, and adverse reactions. Patients will follow up within 30 days post treatment. Patients will be assessed for adverse events, and the safety data will be compared with the original clinical trial.

Primary Objective:

To evaluate the safety and efficacy of ubrogepant (UBRELVY) in patients currently treated with one of the injectable monoclonal antibodies targeting CGRP or the CGRP receptor (Aimovig, Ajovy, or Emgality).

Primary Endpoint:

* Pain freedom at 2 hours.
* Freedom from most bothersome symptom at 2 hours

Secondary Objectives:

To assess improvements with the addition of ubrogepant (UBRELVY) in patients currently treated with one of the injectable monoclonal antibodies targeting CGRP or the CGRP receptor (Aimovig, Ajovy, or Emgality).

Secondary Endpoint:

* Pain relief at 2 hours (this is different from pain freedom: moderate to severe pain reduced to mild or no pain)
* Percentage of patients with sustained pain relief from 2-24 hours after initial dose
* Percentage of patients with sustained pain freedom from 2-24 hours after initial dose
* Pain relief at 2 hours after 2nd dose
* Percentage of patients with sustained pain relief from 2-24 hours after 2nd dose
* Percentage of patients with sustained pain freedom from 2-24 hours after 2nd dose

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Headache, Migraine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Phase IV prospective open label randomized clinical study evaluating safety and efficacy of ubrogepant (UBRELVY) in patients currently treated with one of the injectable monoclonal antibodies targeting CGRP or the CGRP receptor (Aimovig, Ajovy, or Emgality).

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

w/o CGRPmAb

Group Type PLACEBO_COMPARATOR

Ubrogepant 50 MG [Ubrelvy]

Intervention Type DRUG

Ubrogepant 50 MG \[Ubrelvy\]

Ubrogepant 100 MG [Ubrelvy]

Intervention Type DRUG

Ubrogepant 100 MG \[Ubrelvy\]

Tx w/ CGRPmAb

Group Type ACTIVE_COMPARATOR

Ubrogepant 50 MG [Ubrelvy]

Intervention Type DRUG

Ubrogepant 50 MG \[Ubrelvy\]

Ubrogepant 100 MG [Ubrelvy]

Intervention Type DRUG

Ubrogepant 100 MG \[Ubrelvy\]

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ubrogepant 50 MG [Ubrelvy]

Ubrogepant 50 MG \[Ubrelvy\]

Intervention Type DRUG

Ubrogepant 100 MG [Ubrelvy]

Ubrogepant 100 MG \[Ubrelvy\]

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female patients ages 18 to 75 years, at screening (Visit 1).
* At least a 1-year history of migraine with or without aura.
* History of ≥3 monthly headache days of at least moderate severity.
* Study patient currently on CGRPmAbs must be on treatment \> 1 month at screening.
* By history, the patient's migraines typically last between 4 and 72 hours if untreated or treated unsuccessfully and migraine episodes are separated by at least 48 hours of headache pain freedom

Exclusion Criteria

* History of \<3 monthly headache days of at least moderate severity
* Concomitant use of strong CYP3A4 inducers (e.g., phenytoin, barbiturates, rifampin, St. John's Wort)
* Concomitant use of strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin)
* Currently on Botox treatment for CM.
* Concomitant use of gepants as a preventative treatment.
* Current user of illicit drugs, or a history within 1 year prior to screening (visit 1) of drug or alcohol abuse or dependence
* Clinically significant hematologic, endocrine, cardiovascular, pulmonary, gastrointestinal, or neurologic disease. If there is a history of such a disease, but the condition has been stable for more than 1 year prior to screening (visit 1) and is judged by the PI as not likely to interfere with participation in the study, the participant may be included.
* Woman is pregnant, planning to become pregnant during the course of the study, or currently lactating.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No